Study of dsuvia® showing significant reduction in postoperative opioids and better obas scores compared to control group to be presented at the american society of regional anesthesia (asra) annual meeting

Hayward, calif., may 13, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster presentation at the 46th annual regional anesthesiology and acute pain medicine meeting reviewing the results of a study on the intraoperative administration of dsuvia (sufentanil sublingual tablet; sst) 30 mcg for the management of acute pain in an ambulatory surgery center.
ACRX Ratings Summary
ACRX Quant Ranking